Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 5Urologic Neoplasms 1Urinary Bladder Neoplasms 1Pulmonary Embolism 1Adrenal Gland Neoplasms 1

Interventions

Gemcitabine 6Pemetrexed 3Cisplatin 3Carboplatin 3atezolizumab 2Trastuzumab 2Sugammadex 2Paclitaxel 2Neostigmine 2vinflunine 1poly ICLC 1pembrolizumab 1motexafin gadolinium 1montanide ISA 51 1flt3 ligand protein 1enfortumab vedotin 1delta 24-sterol reductase 1daratumumab 1avelumab 1apatorsen 1abemaciclib 1Water 1Thalidomide 1Surveys and Questionnaires 1Saline Solution 1Rocuronium 1Nephroureterectomy 1Nephrectomy 1Neoadjuvant Therapy 1Mitomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Urologic Neoplasms × Nephrectomy × Clear all
NCT03473730 2025-01-30

Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Completed
17 enrolled
Genitourinary

Carcinoma, Renal Cell, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡